Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Lisa Miller interviewed more than two dozen people about the effects weight-loss drugs have had on their romantic ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...